DOCSLIB.ORG

The Diabetic Brain and Cognition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by SZTE Publicatio Repozitórium - SZTE - Repository of Publications J Neural Transm DOI 10.1007/s00702-017-1763-2 NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES - REVIEW ARTICLE The diabetic brain and cognition 1 16 2 3 Peter Riederer • Amos D. Korczyn • Sameh S. Ali • Ovidiu Bajenaru • 4 5 7 Mun Seong Choi • Michael Chopp • Vesna Dermanovic-Dobrota • 8,9,10 11 13,14,15 Edna Gru¨nblatt • Kurt A. Jellinger • Mohammad Amjad Kamal • 12 17 19 Warda Kamal • Jerzy Leszek • Tanja Maria Sheldrick-Michel • 20 18 6 21 Gohar Mushtaq • Bernard Meglic • Rachel Natovich • Zvezdan Pirtosek • 22 23 24 Martin Rakusa • Melita Salkovic-Petrisic • Reinhold Schmidt • 25 26 27 Angelika Schmitt • G. Ramachandra Sridhar • La´szlo´ Ve´csei • 28 29 5,29 6 Zyta Beata Wojszel • Hakan Yaman • Zheng G. Zhang • Tali Cukierman-Yaffe Received: 1 June 2017 / Accepted: 13 July 2017 Ó Springer-Verlag GmbH Austria 2017 Abstract The prevalence of both Alzheimer’s disease (AD) Congress on Vascular Disorders and on literature search and vascular dementia (VaD) is increasing with the aging of using PUBMED, it can be concluded that T2DM is a risk the population. Studies from the last several years have factor for both, AD and VaD, based on a pathology of glu- shown that people with diabetes have an increased risk for cose utilization. This pathology is the consequence of a dementia and cognitive impairment. Therefore, the authors disturbance of insulin-related mechanisms leading to brain of this consensus review tried to elaborate on the role of insulin resistance. Although the underlying pathological diabetes, especially diabetes type 2 (T2DM) in both AD and mechanisms for AD and VaD are different in many aspects, VaD. Based on the clinical and experimental work of sci- the contribution of T2DM and insulin resistant brain state entists from 18 countries participating in the International (IRBS) to cerebrovascular disturbances in both disorders & Peter Riederer Tanja Maria Sheldrick-Michel [email protected] [email protected] Amos D. Korczyn Gohar Mushtaq [email protected] [email protected] Sameh S. Ali Bernard Meglic [email protected]; [email protected] [email protected] Ovidiu Bajenaru Rachel Natovich [email protected] [email protected] Mun Seong Choi Zvezdan Pirtosek [email protected]; [email protected] [email protected] Michael Chopp Martin Rakusa [email protected] [email protected] Vesna Dermanovic-Dobrota Melita Salkovic-Petrisic [email protected] [email protected] Edna Gru¨nblatt Reinhold Schmidt [email protected] [email protected] Kurt A. Jellinger Angelika Schmitt [email protected] [email protected] Mohammad Amjad Kamal G. Ramachandra Sridhar [email protected] [email protected] Warda Kamal La´szlo´ Ve´csei [email protected] [email protected] Jerzy Leszek Zyta Beata Wojszel [email protected] [email protected] 123 P. Riederer et al. cannot be neglected. Therefore, early diagnosis of metabolic BChE Butyrylcholinesterase parameters including those relevant for T2DM is required. BHB Beta-hydroxybutyrate Moreover, it is possible that therapeutic options utilized BIR Brain insulin resistance today for diabetes treatment may also have an effect on the CBF Cerebral blood flow risk for dementia. T2DM/IRBS contribute to pathological CBH Chronic brain hypoperfusion processes in AD and VaD. CSF Cerebrospinal fluid Ct Control Keywords Vascular dementia Á Alzheimer’s disease Á CVR Cerebrovascular reactivity Diabetes mellitus Á Insulin resistance Á Cognition Á DM Diabetes mellitus Neurotransmitters in dementia Á Diabetic brain Á Pathology DNA Desoxyribonucleic acid of dementia Á Experimental model of dementia Á FDG Fluorodeoxyglucose Neurogenesis in dementia Á Epidemiology of dementive FTO Fat-mass and obesity-associated gene disorders Á Imaging in dementia Gd-DTPA Gadolinium-based MRI contrast agent GLP-1 Glucagon-like peptide 1 Abbreviations GLUT3 Glucose transporter 3 Ab Beta-amyloid-protein GM Grey matter AChE Acetylcholinesterase GSK3b Glycogen synthase kinase 3 b AD Alzheimer’s disease HOMA-IR Homeostatic model assessment of insulin AGEs Advanced glycation end products resistance AKT1s1 Proline-rich AKT1 substrate 1 HNE 4-Hydroxynonenal AKT-1 RAC-alpha serine/threonine-protein kinase IDE Insulin degrading enzyme AKT-2 RAC-beta serine/threonine-protein kinase ICV Intracerebroventricular APP Beta-amyloid precursor protein IGF-1R Insulin-like growth factor 1 receptor APOE e4 Apolipoprotein E e4 IR Insulin receptor AQP4 Aquaporin-4 IRBS Insulin resistant brain state ATP Adenosine triphospate IRb Insulin receptor subunit b BBB Blood brain barrier IRS1 Insulin receptor substrate-1 IRS-1pS616 Serin-phosphorylated insulin receptor substrate-1 Hakan Yaman 7 Clinical Hospital Merkur-University, Clinic Vuk Vrhovac, [email protected] Zajcˇeva (Zajceva) 19, 10000 Zagreb, Croatia Zheng G. Zhang 8 Department of Child and Adolescent Psychiatry and [email protected]; [email protected] Psychotherapy, Psychiatric Hospital, University Zurich, Zurich, Switzerland Tali Cukierman-Yaffe [email protected] 9 Neuroscience Center Zurich, University of Zurich and the ETH Zurich, Zurich, Switzerland 1 Center of Mental Health, Department Psychiatry, 10 Zurich Center for Integrative Human Physiology, University Psychosomatics and Psychotherapy, University Hospital of Zurich, 5th Floor Room K118, Wagistrasse 12, Wu¨rzburg, 97080 Wu¨rzburg, Germany 8952 Zurich, Switzerland 2 Center for Aging and Associated Diseases, Helmy Institute of 11 Institute of Clinical Neurobiology, Alberichgasse 5/13, Medical Science, Zewail City of Science and Technology, 1150 Vienna, Austria Giza, Egypt 12 Biomediotronics, Enzymoic, 7 Peterlee Pl, Hebersham, 3 Department of Neurology, Neurosurgery and Psychiatry, NSW 2770, Australia University of Medicine and Pharmacy Carol Davila Bucharest, S Plaiul Independentei 169, Sector 5, 13 King Fahd Medical Research Center, King Abdulaziz 050098 Bucharest, Romania University, P. O. Box 80216, Jeddah 21589, Saudi Arabia 4 Department of Neurology, Hallym Hospital, 900-4 14 Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Jakjeon-dong, Gyeyang-gu, Incheon-si 407-060, Korea Australia 5 Department of Neurology, Henry Ford Hospital, Detroit, 15 Novel Global Community Educational Foundation, Sydney, MI, USA Australia 6 The Center for Successful Aging with Diabetes, 16 Department of Neurology, Tel Aviv University, Endocrinology Institute, Gertner Institute, Sheba Medical 69978 Ramat Aviv, Israel Center, Epidemiology D., Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel 123 The diabetic brain and cognition IRS2 Insulin receptor substrate-2 Introduction ISF Interstitial fluid KAT Kynurenine aminotransferase A causative association between diabetes mellitus (DM) KYNAC Kynurenic acid and cognitive impairment has been suggested based on MCI Mild cognitive impairment clinical, epidemiological, and experimental studies (Ala- MRI Magnet resonance imaging fuzoff et al. 2009; Bitel et al. 2012; Vagelatos and Eslick mTOR Mechanistic target of rapamycin 2013; Carvalho et al. 2015; Feinkohl et al. 2015; Jellinger OS Oxidative stress 2015a). PCAD Pre-clinical AD In fact, recent studies demonstrate a pathophysiological PET Positron emission tomography link between diabetes mellitus type II (T2DM) and cog- PG Postprandial glycemia nitive decline (Jellinger 2015b). This is demonstrated in PIK3CB Phosphatidylinositol-4,5-bisphosphate persons with DM showing that a higher risk of developing 3-kinase catalytic subunit beta isoform Alzheimer’s disease (AD), vascular dementia (VaD) and PIK3CD Phosphatidylinositol-4,5-bisphosphate mixed-type dementia (AD plus cerebrovascular disease), 3-kinase catalytic subunit delta and comorbidity, in particular cerebrovascular disease, PI3 Phosphatidylinositol-3-kinase hypertension, hypercholesterolemia, etc. increases this risk PI3K Phosphoinositid-3-kinase (Jellinger 2015b; Haroon et al. 2015; Kuo et al. 2015). PIP3 Phosphatidylinositol (3,4,5)-triphosphate Insulin resistance predicts medial temporal hyperme- PPARc Peroxisome proliferator-activated receptor tabolism in Mild Cognitive Impairment (MCI) conversion gamma to AD (Willette et al. 2015b). In addition, changes in P-Tau Phospho-Tau-Protein glucose uptake in medial temporal regions in AD predict PYY Peptide YY worse memory performance (Willette et al. 2015a). P53 Phosphoprotein p53 Moreover, DM facilitates cognitive decline in patients with QA Quinolinic acid mild AD compared to those without comorbid DM (Jel- RAGE Receptor for AGEs linger 2015a; Ascher-Svanum et al. 2015). However, the RNA Ribonucleic acid precise mechanisms involved in the development of AD in ROS Reactive oxygen species diabetics are not yet fully understood, and several patho- sAD Sporadic Alzheimer’s disease genic pathways have been discussed (Feinkohl et al. 2015; SGLT2 Sodium/glucose cotransporter 2 Abner et al. 2016; Hao et al. 2015; Chiu et al. 2015; STZ Streptozotocin Verdile et al. 2015; Bedse et al. 2015; De Felice et al. T2DM Type 2 diabetes mellitus 2014), including vascular brain disease, insulin resistance, T1DM Type 1 diabetes mellitus and other metabolic effects on the brain. VaD Vascular dementia In a meta-analysis, Chatterjee et al. (2016) estimated the WM White matter sex-specific relationship between women and men with DM with incident dementia. Fourteen
Recommended publications
  • Supplement 1 Overview of Dystonia Genes

    Supplement 1 Overview of Dystonia Genes

    Supplement 1 Overview of genes that may cause dystonia in children and adolescents Gene (OMIM) Disease name/phenotype Mode of inheritance 1: (Formerly called) Primary dystonias (DYTs): TOR1A (605204) DYT1: Early-onset generalized AD primary torsion dystonia (PTD) TUBB4A (602662) DYT4: Whispering dystonia AD GCH1 (600225) DYT5: GTP-cyclohydrolase 1 AD deficiency THAP1 (609520) DYT6: Adolescent onset torsion AD dystonia, mixed type PNKD/MR1 (609023) DYT8: Paroxysmal non- AD kinesigenic dyskinesia SLC2A1 (138140) DYT9/18: Paroxysmal choreoathetosis with episodic AD ataxia and spasticity/GLUT1 deficiency syndrome-1 PRRT2 (614386) DYT10: Paroxysmal kinesigenic AD dyskinesia SGCE (604149) DYT11: Myoclonus-dystonia AD ATP1A3 (182350) DYT12: Rapid-onset dystonia AD parkinsonism PRKRA (603424) DYT16: Young-onset dystonia AR parkinsonism ANO3 (610110) DYT24: Primary focal dystonia AD GNAL (139312) DYT25: Primary torsion dystonia AD 2: Inborn errors of metabolism: GCDH (608801) Glutaric aciduria type 1 AR PCCA (232000) Propionic aciduria AR PCCB (232050) Propionic aciduria AR MUT (609058) Methylmalonic aciduria AR MMAA (607481) Cobalamin A deficiency AR MMAB (607568) Cobalamin B deficiency AR MMACHC (609831) Cobalamin C deficiency AR C2orf25 (611935) Cobalamin D deficiency AR MTRR (602568) Cobalamin E deficiency AR LMBRD1 (612625) Cobalamin F deficiency AR MTR (156570) Cobalamin G deficiency AR CBS (613381) Homocysteinuria AR PCBD (126090) Hyperphelaninemia variant D AR TH (191290) Tyrosine hydroxylase deficiency AR SPR (182125) Sepiaterine reductase
  • Assessment of a Targeted Gene Panel for Identification of Genes Associated with Movement Disorders

    Assessment of a Targeted Gene Panel for Identification of Genes Associated with Movement Disorders

    Supplementary Online Content Montaut S, Tranchant C, Drouot N, et al; French Parkinson’s and Movement Disorders Consortium. Assessment of a targeted gene panel for identification of genes associated with movement disorders. JAMA Neurol. Published online June 18, 2018. doi:10.1001/jamaneurol.2018.1478 eMethods. Supplemental methods. eTable 1. Name, phenotype and inheritance of the genes included in the panel. eTable 2. Probable pathogenic variants identified in a cohort of 23 patients with cerebellar ataxia using WES analysis. eTable 3. Negative cases in a cohort of 23 patients with cerebellar ataxia studied using WES analysis. eTable 4. Variants of unknown significance (VUSs) identified in the cohort. eFigure 1. Examples of pedigrees of cases with identified causative variants. eFigure 2. Pedigrees suggesting mendelian inheritance in negative cases. eFigure 3. Examples of pedigrees of cases with identified VUSs. eResults. Supplemental results. This supplementary material has been provided by the authors to give readers additional information about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 eMethods. Supplemental methods Patients selection In the multicentric, prospective study, patients were selected from 25 French, 1 Luxembourg and 1 Algerian tertiary MDs centers between September 2014 and July 2016. Inclusion criteria were patients (1) who had developed one or several chronic MDs (2) with an age of onset below 40 years and/or presence of a family history of MDs. Patients suffering from essential tremor, tic or Gilles de la Tourette syndrome, pure cerebellar ataxia or with clinical/paraclinical findings suggestive of an acquired cause were excluded.
  • 1 Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental

    1 Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental

    Page 1 of 255 Diabetes Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy Oliver J. Freeman1,2, Richard D. Unwin2,3, Andrew W. Dowsey2,3, Paul Begley2,3, Sumia Ali1, Katherine A. Hollywood2,3, Nitin Rustogi2,3, Rasmus S. Petersen1, Warwick B. Dunn2,3†, Garth J.S. Cooper2,3,4,5* & Natalie J. Gardiner1* 1 Faculty of Life Sciences, University of Manchester, UK 2 Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK 3 Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK 4 School of Biological Sciences, University of Auckland, New Zealand 5 Department of Pharmacology, Medical Sciences Division, University of Oxford, UK † Present address: School of Biosciences, University of Birmingham, UK *Joint corresponding authors: Natalie J. Gardiner and Garth J.S. Cooper Email: [email protected]; [email protected] Address: University of Manchester, AV Hill Building, Oxford Road, Manchester, M13 9PT, United Kingdom Telephone: +44 161 275 5768; +44 161 701 0240 Word count: 4,490 Number of tables: 1, Number of figures: 6 Running title: Metabolic dysfunction in diabetic neuropathy 1 Diabetes Publish Ahead of Print, published online October 15, 2015 Diabetes Page 2 of 255 Abstract High glucose levels in the peripheral nervous system (PNS) have been implicated in the pathogenesis of diabetic neuropathy (DN). However our understanding of the molecular mechanisms which cause the marked distal pathology is incomplete. Here we performed a comprehensive, system-wide analysis of the PNS of a rodent model of DN.
  • Peter Riederer

    Peter Riederer

    Profiles (List of Publications) February 25, 2016 Peter Riederer 1 1992 (419) Frölich L, Riederer P (1992) Demenz vom Alzheimer-Typ: Biochemische Befunde und ätiologische Hypothesen. Therapiewoche 42 (9):500-505 (420) Riederer P, Lange KW, Kornhuber J, Danielczyk W (1992) Glutamatergic-Dopaminergic Balance in the Brain. Arzneim-Forsch/Drug Res 42 (I):265-268 (421) Gerlach M, Riederer P (1992) Biochemische Grundlagen der Psychosen. In: Der Medizinische Notfall VI. Proceedings, Interdisziplinäres Forum für Med. Fortbildung, Neuhofen/Ybbs, pp 65-71 (422) Riederer P, Laux G, Pöldinger W (1992) Neuro-Psychopharmaka, Bd. 1, SpringerVerlag WienNewYork (423) Berger W, Riederer P (1992) 10.2 Neurotransmitter-Regelkreise. Riederer P, Laux G, Pöldinger (eds) Neuro-Psychopharmaka, Bd. 1. Springer-Verlag WienNewYork, pp 225-271 (424) Müller WE, Riederer P, Kienzel E (1992) 9. Grundlegende Aspekte zur Neurotransmission. Riederer P, Laux G, Pöldinger (eds) Neuro-Psychopharmaka, Bd. 1. Springer-Verlag WienNewYork, pp 222-248 (425) Sofic E, Riederer P, Schmidt B, Fritze J, Kollegger H, Dierks T, Beckmann H (1992) Biogenic amines and metabolites in CSF from patients with HIV infection. Biogenic Amines 8 (5):293-298 (426) Riederer P, Lange KW (1992) Pathogenesis of Parkinson´s disease. Current Opinion in Neurology and Neurosurgery 5:295-300 (427) Gerlach M, Riederer P, Youdim MBH (1992) The molecular pharmacoloy of L-deprenyl. European Journal of Pharmacology - Molecular Pharmacology Section 226:97-108 (428) Hiemke C, Baumann P, Breyer-Pfaff U, Gold R, Klotz U, Müller-Oerlinghausen B, Rao M-L, Riederer P, Wetzel H, Wiedemann K (1992) Drug Monitoring in Psychiatric Patients: Which Approach is Useful to Improve Psychopharmacotherapy? Pharmacopsychiat 25:72-74 2 (429) Youdim MBH, Riederer P (1992) Iron in the Brain, and Parkinson´s Disease.
  • Proteomic Characterization of Synaptosomes from Human Substantia Nigra Indicates Altered Mitochondrial Translation in Parkinson's Disease

    Proteomic Characterization of Synaptosomes from Human Substantia Nigra Indicates Altered Mitochondrial Translation in Parkinson's Disease

    UCSF UC San Francisco Previously Published Works Title Proteomic Characterization of Synaptosomes from Human Substantia Nigra Indicates Altered Mitochondrial Translation in Parkinson's Disease. Permalink https://escholarship.org/uc/item/01d6j0mz Journal Cells, 9(12) ISSN 2073-4409 Authors Plum, Sarah Eggers, Britta Helling, Stefan et al. Publication Date 2020-12-02 DOI 10.3390/cells9122580 Peer reviewed eScholarship.org Powered by the California Digital Library University of California cells Article Proteomic Characterization of Synaptosomes from Human Substantia Nigra Indicates Altered Mitochondrial Translation in Parkinson’s Disease 1, 1,2, 1 1,2 3 Sarah Plum y, Britta Eggers y , Stefan Helling , Markus Stepath , Carsten Theiss , Renata E. P. Leite 4,5, Mariana Molina 4, Lea T. Grinberg 4,6, Peter Riederer 7,8, Manfred Gerlach 9, 1,2, 1,2, , Caroline May z and Katrin Marcus * z 1 Medizinisches Proteom-Center, Medical Faculty, Ruhr-University Bochum, 44801 Bochum, Germany; [email protected] (S.P.); [email protected] (B.E.); [email protected] (S.H.); [email protected] (M.S.); [email protected] (C.M.) 2 Medical Proteome Analysis, Center for Proteindiagnostics (PRODI), Ruhr-University Bochum, 44801 Bochum, Germany 3 Department of Cytology, Institute of Anatomy, Ruhr-University Bochum, 44780 Bochum, Germany; [email protected] 4 Department of Pathology, LIM22, University of Sao Paulo Medical School, Sao Paulo 01246-903, Brazil; [email protected] (R.E.P.L.); [email protected] (M.M.); [email protected]
  • Supplemental Table 10

    Supplemental Table 10

    Supplemental Table 10: Dietary Impact on the Heart Sulfhydrome DR/AL Accession Alternate Molecular Cysteine Spectral Protein Name Number ID Weight Residues Count Ratio P‐value Ig lambda‐2 chain C region P01844 Iglc2 11 kDa 3 C 16.000 0.00101 Gelsolin P13020 (+1) Gsn 86 kDa 7 C 11.130 0.00133 Glutamate‐‐cysteine ligase regulatory subunit O09172 Gclm 31 kDa 6 C 10.200 0.0307 Ig gamma‐3 chain C region P03987 44 kDa 10 C 7.636 0.0005 Ferritin heavy chain P09528 Fth1 21 kDa 3 C 6.182 0.02617 Antithrombin‐III P32261 Serpinc1 52 kDa 9 C 5.333 0.03116 Bisphosphoglycerate mutase P15327 Bpgm 30 kDa 3 C 4.645 0.01998 Vitamin D‐binding protein Q9QVP4 Gc 54 kDa 28 C 4.541 0.0206 Properdin P11680 Cfp 50 kDa 44 C 3.692 0.0227 Complement factor B P01867 (+1) Cfb 85 kDa 20 C 3.636 0.01126 Transforming growth factor beta‐1 P04202 Tgfb1 44 kDa 12 C 3.273 0.00601 Ferritin light chain 1 P29391 Ftl1 21 kDa 1 C 3.250 0.0204 Ig lambda‐1 chain C region Q9CPV4‐2 12 kDa 3 C 2.844 0.02618 Kininogen‐1 Q8K182 Kng1 73 kDa 19 C 2.840 0.01359 Beta‐2‐glycoprotein 1 Q01339 Apoh 39 kDa 23 C 2.691 0.00579 Complement C3 P01027 C3 186 kDa 27 C 2.556 0.00991 Complement factor I P02088 Cfi 67 kDa 40 C 2.324 0.02636 Ig heavy chain V region 102 P01750 13 kDa 3 C 16.200 0.1642 Afamin O89020 (+1) Afm 69 kDa 34 C 14.400 0.07963 Dehydrogenase/reductase SDR family member 11 Q3U0B3 Dhrs11 28 kDa 8 C 10.400 0.09207 Myosin light chain 4 P09541 Myl4 21 kDa 2 C 9.908 0.23919 Myeloperoxidase P11247 Mpo 81 kDa 16 C 8.800 0.40708 Myosin regulatory light chain 2, skeletal muscle isoform P97457
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories

    Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories

    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA Co-Expressed Gene List in LUAD

    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
  • Growth and Gene Expression Profile Analyses of Endometrial Cancer Cells Expressing Exogenous PTEN

    Growth and Gene Expression Profile Analyses of Endometrial Cancer Cells Expressing Exogenous PTEN

    [CANCER RESEARCH 61, 3741–3749, May 1, 2001] Growth and Gene Expression Profile Analyses of Endometrial Cancer Cells Expressing Exogenous PTEN Mieko Matsushima-Nishiu, Motoko Unoki, Kenji Ono, Tatsuhiko Tsunoda, Takeo Minaguchi, Hiroyuki Kuramoto, Masato Nishida, Toyomi Satoh, Toshihiro Tanaka, and Yusuke Nakamura1 Laboratories of Molecular Medicine [M. M-N., M. U., K. O., T. M., T. Ta., Y. N.] and Genome Database [T. Ts.], Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan; Department of Obstetrics and Gynecology, School of Medicine, Kitasato University, Sagamihara 228-8555, Japan [H. K.]; Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba 305-8576, Japan [M. N.]; and Department of Obstetrics and Gynecology, Ibaraki Seinan Central Hospital, Tsukuba 306-0433, Japan [T. S.] ABSTRACT Akt/protein kinase B, cell survival, and cell proliferation (8). Over- expression of PTEN can decrease cell proliferation and tumorigenicity The PTEN tumor suppressor gene encodes a multifunctional phospha- (9, 10), an observation attributed to the ability of PTEN to induce cell tase that plays an important role in inhibiting the phosphatidylinositol-3- cycle arrest and apoptosis (11, 12). kinase pathway and downstream functions that include activation of Akt/protein kinase B, cell survival, and cell proliferation. Enforced ex- Thus, lack of PTEN expression may affect a complex set of pression of PTEN in various cancer cell lines decreases cell proliferation transcriptional targets. However, no systematic assessment of PTEN- through arrest of the cell cycle, accompanied in some cases by induction regulated targets in cancer cells has been reported to date.
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al

    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
  • Treatment for Disease Modification in Chronic Neurodegeneration

    Treatment for Disease Modification in Chronic Neurodegeneration

    cells Review Perspective: Treatment for Disease Modification in Chronic Neurodegeneration Thomas Müller 1,* , Bernhard Klaus Mueller 1 and Peter Riederer 2,3 1 Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Gartenstr. 1, 13088 Berlin, Germany; [email protected] 2 Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, Margarete-Höppel-Platz 1, 97080 Würzburg, Germany; [email protected] 3 Department of Psychiatry, Southern Denmark University Odense, J.B. Winslows Vey 18, 5000 Odense, Denmark * Correspondence: [email protected] Abstract: Symptomatic treatments are available for Parkinson’s disease and Alzheimer’s disease. An unmet need is cure or disease modification. This review discusses possible reasons for negative clinical study outcomes on disease modification following promising positive findings from experi- mental research. It scrutinizes current research paradigms for disease modification with antibodies against pathological protein enrichment, such as α-synuclein, amyloid or tau, based on post mortem findings. Instead a more uniform regenerative and reparative therapeutic approach for chronic neurodegenerative disease entities is proposed with stimulation of an endogenously existing repair system, which acts independent of specific disease mechanisms. The repulsive guidance molecule A pathway is involved in the regulation of peripheral and central neuronal restoration. Therapeutic antagonism of repulsive guidance molecule A reverses neurodegeneration according to experimental Citation: Müller, T.; Mueller, B.K.; outcomes in numerous disease models in rodents and monkeys. Antibodies against repulsive guid- Riederer, P. Perspective: Treatment for ance molecule A exist. First clinical studies in neurological conditions with an acute onset are under Disease Modification in Chronic Neurodegeneration. Cells 2021, 10, way.
  • Association Between a Null Mutation in the Human Ciliary Neurotrophic Factor (CNTF) Gene and Increased Incidence of Psychiatric Diseases?

    Association Between a Null Mutation in the Human Ciliary Neurotrophic Factor (CNTF) Gene and Increased Incidence of Psychiatric Diseases?

    ELSEVIER Neuroscience Letters 203 (1996) 109-110 Association between a null mutation in the human ciliary neurotrophic factor (CNTF) gene and increased incidence of psychiatric diseases? Johannes Thome a,*, Johannes Kornhuber a, Alessandra Baumer b, Michael R6sler a, Helmut Beckmann a, Peter Riederer a aDepartment of Psychiatry, University of Wfirzburg, Fiichsleinstrafle 15, 97080 Wfirzburg, Germany blnstitute of Human Genetics, University of Wfirzburg, Am Hubland, 97074 Wiirzburg, Germany Received 16 October 1995; revised version received 6 December 1995; accepted 6 December 1995 Abstract We report a possible association between a null mutation in the human ciliary neurotrophic factor (CNTF) gene and psychiatric dis- eases. Prior findings that the mutant allele frequency is not significantly elevated in patients suffering from neurological diseases are confirmed. The frequency of the mutant allele was higher among psychiatric patients (0.192, n = 297) than among healthy controls and neurological patients (0.142, n = 267). This difference (one-tailed 2 x 2 chi-square test, P < 0.05) might be evidence that disturbances in the neurotrophic factor system could play a crucial role in the etiopathogenesis of psychiatric disorders, mainly psychoses. Keywords: Ciliary neurotrophic factor; Genetics; Mutation; Neurodevelopment; Neurotrophic factor; Psychiatry; Psychoses Neurodevelopmental deficits, disturbances of the quency in a Caucasian population was determined for the cell migration and dysconnections of neuronal and glial first time. structures are currently discussed as possible pathome- Inpatients (208 neurological: 112 female, 96 male; chanisms for psychiatric disorders, mainly endogenous and 297 psychiatric: 155 female, 142 male) suffering psychoses including schizophrenia [2,3,9] and manic- from various diseases, as well as 59 age- and sex-matched depressive disorders, severe brain diseases with until now healthy subjects (31 female, 28 male) were examined unknown pathogenesis and putative genetic and environ- (mean age __.